{
    "symbol": "JNCE",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-05 17:51:02",
    "content": " Data from previously published studies with PD-1 inhibitors and PD-1 inhibitor naive ovarian cancer and PD-1 inhibitor experienced renal cell carcinoma have reported response rates of approximately 9% and 13%, respectively. In SELECT, we are studying two doses of Vopra in combination with Pimi, compared to Pimi alone in biomarker selected patients with metastatic non-small cell lung cancer, who are PD-1 inhibitor naive and have progressed on a platinum-based chemotherapy regimen. Your line is open. Your line is open. Your line is open. Your line is open. Your line is open."
}